Skip to main content
GANX
NASDAQ Life Sciences

Gain Therapeutics 10-Q: Going Concern Warning With $11.7M Cash, Runway Into Q2 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.08
Mkt Cap
$47.135M
52W Low
$0.94
52W High
$4.34
52W Position info
15% above low
Off High info
75% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

GANX is trading near its 52-week low of $0.94 (15% above the low).

Summary

Gain Therapeutics posted a narrower Q3 loss ($3.16M, or $0.07 per share) but disclosed substantial doubt about its ability to continue as a going concern, with $11.7M in cash that runs only into Q2 2027 and a Phase 2 start pushed to Q1 2027.


Key Events · Earnings and Guidance · GANX

  • Going Concern Doubt Disclosed

    Management states $11.7M of cash at September 30, 2026 will not fund operations for at least 12 months from issuance and that additional capital is needed to continue beyond the second quarter of 2027.

  • Q3 Loss Narrows to $3.16M

    Net loss was $3.16M, or $0.07 per share, versus $5.28M, or $0.15 per share, a year earlier; R&D fell to $1.42M from $2.85M and G&A to $1.78M from $1.94M.

  • ATM Remains the Funding Source

    1,941,962 shares were sold in the nine months at an average $1.96 for $3.8M gross, and a further 205,579 shares at an average $1.58 for $0.33M gross between October 1 and November 6, 2026.

  • Litigation Motion to Dismiss Denied

    The court denied the motion to dismiss the Schwartzberg amended complaint on October 26, 2026; the suit seeks damages in excess of $3.1M and the company answered on November 9, 2026.


Analysis · GANX · Life Sciences

The Q3 numbers themselves are an improvement — net loss narrowed to $3.16M from $5.28M a year ago as R&D fell to $1.42M from $2.85M — but the balance sheet is the story. Cash dropped to $11.7M from $20.8M at year-end, and management states plainly that this will not fund operations for 12 months from issuance and that new capital is needed to get past the second quarter of 2027. That is a going-concern qualification, and the only committed funding source is the 2024 ATM, which has been the company's lifeline: 1.94M shares sold in the first nine months at an average $1.96, plus another 205,579 shares at $1.58 between October 1 and November 6. Layered on top is litigation risk — the court denied the motion to dismiss the Schwartzberg complaint on October 26, 2026, and the case seeks damages in excess of $3.1M, roughly a quarter of the remaining cash. The Phase 2 rexaceract study is now targeted for Q1 2027 after a protocol redesign, so there is no near-term clinical readout to offset the financing overhang.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GANX was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.1M. The 52-week trading range was $0.94 to $4.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GANX - Latest Insights

GANX
Oct 01, 2026, 9:28 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $1.16 info
Change: -$0.5814 (-33%) info
Market Cap: $48.444M info
GANX
Oct 01, 2026, 9:16 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.16 info
Change: -$0.5939 (-34%) info
Market Cap: $48.444M info
GANX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.00
Real-time Price: $1.16 info
Change: -$0.844 (-42%) info
Market Cap: $48.444M info
GANX
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $1.16 info
Change: -$0.9014 (-44%) info
Market Cap: $48.444M info
GANX
Jul 16, 2026, 7:53 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.68
Real-time Price: $1.16 info
Change: -$0.5214 (-31%) info
Market Cap: $48.444M info